Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants PRIME scheme access to Bluebird's Lentiglobin and Juno's JCAR-015

Sep. 22, 2016

AstraZeneca withdraws MAA for cediranib

Sep. 22, 2016

EMA validates BMS' application to extend Opdivo indications

Sep. 21, 2016

EMA issues positive opinion on the MAA for SomaKit TOC

Sep. 20, 2016

Pfizer receives positive CHMP opinion for Ibrance in Europe

Sep. 19, 2016

EMA committee grants positive opinion for conditional approval of Ninlaro

Sep. 19, 2016

EMA committee recommends approval of Parsabiv in E.U.

Sep. 19, 2016

EMA committee recommends E.U. approval of Stelara for moderate to severely active Crohn's disease

Sep. 19, 2016

EMA's CHMP recommends approval of Glyxambi for adults with type 2 diabetes

Sep. 19, 2016

EMA's CHMP recommends conditional approval of Lilly's olaratumab

Sep. 16, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...